Inventor · disambiguated record
Jesper Gromada
Also filed as: GROMADA JESPER · GROMADA JESPER A
48 granted patents·37 pending applications·137 citations·filing 2010–2025
98Inventor score
Top patents by PatentIndex Score
85 records- 0195US11180757B117β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 23, 2021·3 cites·30 claims
- 0294US11702700B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2021·Granted Jul 18, 2023·4 cites·27 claims
- 0394US10787647B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 29, 2020·10 cites·52 claims
- 0494US10618968B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2018·Granted Apr 14, 2020·7 cites·34 claims
- 0594US10023644B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2016·Granted Jul 17, 2018·14 cites·14 claims
- 0694US9718881B2Anti-Activin A antibodies and uses thereofREGENERON PHARMA·Filed 2014·Granted Aug 1, 2017·21 cites·44 claims
- 0793US11820826B2Anti-NPR1 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Nov 21, 2023·2 cites·14 claims
- 0893US9644018B2Antibody modulators of APLNRREGENERON PHARMA·Filed 2015·Granted May 9, 2017·13 cites·11 claims
- 0992US11753628B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·1 cites·26 claims
- 1092US11045522B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2018·Granted Jun 29, 2021·3 cites·5 claims
- 1192US10961583B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2018·Granted Mar 30, 2021·9 cites·29 claims
- 1291US11608381B2Methods of treatment using a leptin receptor agonist antibodyREGENERON PHARMA·Filed 2019·Granted Mar 21, 2023·4 cites·9 claims
- 1391US10253102B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2018·Granted Apr 9, 2019·7 cites·29 claims
- 1491US9657099B2Anti-glucagon antibodiesREGENERON PHARMA·Filed 2015·Granted May 23, 2017·10 cites·14 claims
- 1590US11535675B2Antigen-binding proteins that antagonize leptin receptorREGENERON PHARMA·Filed 2020·Granted Dec 27, 2022·2 cites·25 claims
- 1690US10550192B2Antigen-binding proteins that antagonize leptin receptorREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·4 cites·24 claims
- 1788US11306148B2Anti-NPR1 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Apr 19, 2022·3 cites·11 claims
- 1887US12090193B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Granted Sep 17, 2024·0 cites·10 claims
- 1987US10626173B2Method for treating pathological angiogenesis by administering an antibody that inhibits APLNRREGENERON PHARMA·Filed 2018·Granted Apr 21, 2020·2 cites·20 claims
- 2087US10526403B2Anti-activin A antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Jan 7, 2020·4 cites·43 claims
- 2186US2025051465A1Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2286US2025066463A1Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2386US2024141305A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2485US2025000949A1Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2584US12286677B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2023·Granted Apr 29, 2025·0 cites·14 claims
- 2684US11845963B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Dec 19, 2023·1 cites·12 claims
- 2784US11485958B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·1 cites·40 claims
- 2883US2024091301A1APLNR Modulators and Uses ThereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2982US10947310B2Fusion protein comprising apelin and an anti-APLNR antibodyREGENERON PHARMA·Filed 2018·Granted Mar 16, 2021·1 cites·20 claims
- 3082US10259870B2Anti-ANGPTL8 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Apr 16, 2019·2 cites·3 claims
- 3182US10189901B2Methods for improving cardiac function by administering an antibody that activates APLNRREGENERON PHARMA·Filed 2017·Granted Jan 29, 2019·2 cites·13 claims
- 3282US2024309103A1Anti-npr1 antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3381US11377502B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 5, 2022·1 cites·5 claims
- 3481US2025320301A1Methods of treatment using a leptin receptor agonist antibodyREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3581US2024059780A1Anti-npr1 antibodies and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3680US10548302B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·1 cites·30 claims
- 3780US2023031669A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3880US2023312699A1Anti-activin a antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3979US12275792B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2021·Granted Apr 15, 2025·0 cites·14 claims
- 4079US11834500B2Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Dec 5, 2023·1 cites·9 claims
- 4179US10155811B2APLNR modulators and uses thereofREGENERON PHARMA·Filed 2014·Granted Dec 18, 2018·2 cites·20 claims
- 4278US2023416384A1Methods of treating severe insulin resistance by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4377US12371503B2Methods of treatment using a leptin receptor agonist antibodyREGENERON PHARMA·Filed 2022·Granted Jul 29, 2025·0 cites·12 claims
- 4477US2025101119A1Methods of treating urea cycle disorders by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4577US2025171622A1Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4676US11779633B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Oct 10, 2023·0 cites·5 claims
- 4776US2025333737A117ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4876US2025304656A1Nucleic acids encoding anchor modified antibodies and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4976US2022127348A1Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 5075US11642390B2Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibodyREGENERON PHARMA·Filed 2021·Granted May 9, 2023·0 cites·18 claims
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jesper Gromada files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →